While its "AAA" credit rating, robust free cash flow, and low-debt profile offer a defensive haven in a volatile market, the ...
Johnson & Johnson is upgraded to Buy and Pfizer to Hold reflecting improved profitability outlooks post-Q4 2025 earnings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results